{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T23:06:01Z","timestamp":1777331161972,"version":"3.51.4"},"reference-count":33,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,10,16]],"date-time":"2020-10-16T00:00:00Z","timestamp":1602806400000},"content-version":"vor","delay-in-days":654,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"No-profit ARCO (Associazione Ricerche e Cure in Oncologia) Foundation","award":["non grant number applied"],"award-info":[{"award-number":["non grant number applied"]}]}],"content-domain":{"domain":["esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2019]]},"DOI":"10.1136\/esmoopen-2019-000489","type":"journal-article","created":{"date-parts":[[2019,3,9]],"date-time":"2019-03-09T05:19:22Z","timestamp":1552108762000},"page":"e000489","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["Benefit from anti-EGFRs in RAS and BRAF wild-type metastatic transverse colon cancer: a clinical and molecular proof of concept study"],"prefix":"10.1016","volume":"4","author":[{"given":"Chiara","family":"Cremolini","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matteo","family":"Benelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisa","family":"Fontana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Filippo","family":"Pagani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniele","family":"Rossini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1560-2253","authenticated-orcid":false,"given":"Giovanni","family":"Fuc\u00e0","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adele","family":"Busico","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Conca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samantha","family":"Di Donato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fotios","family":"Loupakis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Schirripa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Lonardi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beatrice","family":"Borelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0548-7092","authenticated-orcid":false,"given":"Elena","family":"Ongaro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katherine","family":"Eason","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5306-3596","authenticated-orcid":false,"given":"Federica","family":"Morano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariaelena","family":"Casagrande","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matteo","family":"Fassan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anguraj","family":"Sadanandam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Filippo","family":"de Braud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alfredo","family":"Falcone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Filippo","family":"Pietrantonio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1136\/esmoopen-2019-000489_bb0010","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.critrevonc.2015.05.016","article-title":"First-line anti-EGFR monoclonal antibodies in panRAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis","volume":"96","author":"Pietrantonio","year":"2015","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1136\/esmoopen-2019-000489_bb0015","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.ejca.2015.01.054","article-title":"Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: a meta-analysis","volume":"51","author":"Pietrantonio","year":"2015","journal-title":"Eur J Cancer"},{"key":"10.1136\/esmoopen-2019-000489_bb0020","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1634\/theoncologist.2015-0171","article-title":"Single-agent panitumumab in frail elderly patients with advanced Ras and BRAF wild-type colorectal cancer: challenging drug label to light up new hope","volume":"20","author":"Pietrantonio","year":"2015","journal-title":"Oncologist"},{"key":"10.1136\/esmoopen-2019-000489_bb0025","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2016.4227","article-title":"Prognostic survival associated with left-sided vs right-sided colon cancer","volume":"3","author":"Petrelli","year":"2017","journal-title":"JAMA Oncol"},{"key":"10.1136\/esmoopen-2019-000489_bb0030","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1093\/annonc\/mdx175","article-title":"Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials","volume":"28","author":"Arnold","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1136\/esmoopen-2019-000489_bb0035","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/dju427","article-title":"Primary tumor location as a prognostic factor in metastatic colorectal cancer","volume":"107","author":"Loupakis","year":"2015","journal-title":"J Natl Cancer Inst"},{"issue":"15_suppl","key":"10.1136\/esmoopen-2019-000489_bb0040","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2017.35.15_suppl.3538","article-title":"Velour trial biomarkers update: impact of Ras, BRAF, and sidedness on aflibercept activity","volume":"35","author":"Wirapati","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1136\/esmoopen-2019-000489_bb0045","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1634\/theoncologist.2016-0084","article-title":"Location of primary tumor and benefit from anti-epidermal growth factor receptor monoclonal antibodies in patients with Ras and BRAF wild-type metastatic colorectal cancer","volume":"21","author":"Moretto","year":"2016","journal-title":"Oncologist"},{"key":"10.1136\/esmoopen-2019-000489_bb0050","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1093\/annonc\/mdx119","article-title":"Primary tumor sidedness has an impact on prognosis and treatment outcome in metastatic colorectal cancer: results from two randomized first-line panitumumab studies","volume":"28","author":"Boeckx","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1136\/esmoopen-2019-000489_bb0055","doi-asserted-by":"crossref","unstructured":"STejpar, SStintzing, FCiardiello, et al. Prognostic and Predictive Relevance of Primary Tumor Location in Patients With RAS Wild-Type Metastatic Colorectal Cancer: Retrospective Analyses of the CRYSTAL and FIRE-3 Trials. JAMA Oncol (Published Online First: 10 October 2016).","DOI":"10.1001\/jamaoncol.2016.3797"},{"key":"10.1136\/esmoopen-2019-000489_bb0060","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.ejca.2016.10.007","article-title":"The relevance of primary tumour location in patients with metastatic colorectal cancer: a meta-analysis of first-line clinical trials","volume":"70","author":"Holch","year":"2017","journal-title":"Eur J Cancer"},{"issue":"15_suppl","key":"10.1136\/esmoopen-2019-000489_bb0065","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2017.35.15_suppl.3503","article-title":"Primary (1\u00b0) tumor location as an independent prognostic marker from molecular features for overall survival (OS) in patients (PTS) with metastatic colorectal cancer (mCRC): analysis of CALGB \/ SWOG 80405 (Alliance)","volume":"35","author":"Venook","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1136\/esmoopen-2019-000489_bb0070","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1056\/NEJMoa1403108","article-title":"Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer","volume":"371","author":"Loupakis","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1136\/esmoopen-2019-000489_bb0075","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdy140","article-title":"Primary tumor sidedness and benefit from FOLFOXIRI plus bevacizumab as initial therapy for metastatic colorectal cancer. retrospective analysis of the tribe trial by GONO","author":"Cremolini","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1136\/esmoopen-2019-000489_bb0080","doi-asserted-by":"crossref","first-page":"359","DOI":"10.6004\/jnccn.2018.0021","article-title":"NCCN guidelines insights: colon cancer, version 2.2018","volume":"16","author":"Benson","year":"2018","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1136\/esmoopen-2019-000489_bb0085","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1038\/nrclinonc.2015.129","article-title":"First-line chemotherapy for mCRC\u2014a review and evidence-based algorithm","volume":"12","author":"Cremolini","year":"2015","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1136\/esmoopen-2019-000489_bb0090","doi-asserted-by":"crossref","first-page":"86356","DOI":"10.18632\/oncotarget.21169","article-title":"Comparative molecular analyses of left-sided colon, right-sided colon, and rectal cancers","volume":"8","author":"Salem","year":"2017","journal-title":"Oncotarget"},{"key":"10.1136\/esmoopen-2019-000489_bb0095","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1158\/1078-0432.CCR-17-2484","article-title":"Classifying colorectal cancer by tumor location rather than sidedness highlights a continuum in mutation profiles and consensus molecular subtypes","volume":"24","author":"Loree","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1136\/esmoopen-2019-000489_bb0100","doi-asserted-by":"crossref","first-page":"3009","DOI":"10.1093\/annonc\/mdx546","article-title":"Negative hyper-selection of metastatic colorectal cancer patients for anti-EGFR monoclonal antibodies: the PRESSING case-control study","volume":"28","author":"Cremolini","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1136\/esmoopen-2019-000489_bb0105","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1038\/nm.3967","article-title":"The consensus molecular subtypes of colorectal cancer","volume":"21","author":"Guinney","year":"2015","journal-title":"Nat Med"},{"key":"10.1136\/esmoopen-2019-000489_bb0110","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1093\/annonc\/mdy197","article-title":"Temozolomide and irinotecan (TEMIRI regimen) as salvage treatment of irinotecan-sensitive advanced colorectal cancer patients bearing MGMT methylation","volume":"29","author":"Morano","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1136\/esmoopen-2019-000489_bb0115","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djx089","article-title":"ALK, ROS1, and NTRK rearrangements in metastatic colorectal cancer","volume":"109","author":"Pietrantonio","year":"2017","journal-title":"J Natl Cancer Inst"},{"key":"10.1136\/esmoopen-2019-000489_bb0120","article-title":"A low-cost multiplex biomarker assay Stratifies colorectal cancer patient samples into Clinically-Relevant subtypes","volume":"174847","author":"Ragulan","year":"2017","journal-title":"bioRxiv"},{"issue":"suppl_10","key":"10.1136\/esmoopen-2019-000489_bb0125","article-title":"145OValidated nCounter platform to stratify colorectal cancer (CRC) into consensus molecular subtypes (CMS) and CRCassigner subtypes in Asian population","volume":"28","author":"Fontana","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1136\/esmoopen-2019-000489_bb0130","unstructured":"Search. GDC. Available:https:\/\/portal.gdc.cancer.gov\/legacy-archive\/search\/f[Accessed accessed 20 Nov 2018]."},{"key":"10.1136\/esmoopen-2019-000489_bb0135","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.2004088","article-title":"Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal","volume":"6","author":"Gao","year":"2013","journal-title":"Sci Signal"},{"key":"10.1136\/esmoopen-2019-000489_bb0140","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","article-title":"The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data","volume":"2","author":"Cerami","year":"2012","journal-title":"Cancer Discov"},{"key":"10.1136\/esmoopen-2019-000489_bb0145","series-title":"Contribute to Sage-Bionetworks\/CMSclassifier development by creating an account on GitHub","author":"Sage Bionetworks","year":"2018"},{"key":"10.1136\/esmoopen-2019-000489_bb0150","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1158\/2159-8290.CD-14-1211","article-title":"HER2 activating mutations are targets for colorectal cancer treatment","volume":"5","author":"Kavuri","year":"2015","journal-title":"Cancer Discov"},{"key":"10.1136\/esmoopen-2019-000489_bb0155","unstructured":"The Comprehensive R Archive Network. Available:https:\/\/cran.r-project.org\/[Accessed20 Nov 2018]."},{"key":"10.1136\/esmoopen-2019-000489_bb0160","unstructured":"Cosmic. COSMIC - Catalogue of Somatic Mutations in Cancer. Available: https:\/\/cancer.sanger.ac.uk\/cosmic [Accessed 20 Nov 2018]."},{"key":"10.1136\/esmoopen-2019-000489_bb0165","doi-asserted-by":"crossref","unstructured":"Somatic DNA mutations, MSI status, mutational load (ML): association with overall survival (OS) in patients (PTS) with metastatic colorectal cancer (mCRC) of CALGB\/SWOG 80405 (Alliance). Journal of Clinical Oncology;35(15_suppl). (accessed 3 Jun 2018)http:\/\/ascopubs.org\/doi\/abs\/10.1200\/JCO.2017.35.15_suppl.3504","DOI":"10.1200\/JCO.2017.35.15_suppl.3504"},{"key":"10.1136\/esmoopen-2019-000489_bb0170","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1158\/2159-8290.CD-17-0891","article-title":"Longitudinal liquid biopsy and mathematical modeling of clonal evolution forecast time to treatment failure in the PROSPECT-C phase II colorectal cancer clinical trial","volume":"8","author":"Khan","year":"2018","journal-title":"Cancer Discov"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702920301794?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702920301794?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/esmoopen-2019-000489","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T20:22:49Z","timestamp":1761855769000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702920301794"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019]]},"references-count":33,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019]]}},"alternative-id":["S2059702920301794"],"URL":"https:\/\/doi.org\/10.1136\/esmoopen-2019-000489","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2019]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Benefit from anti-EGFRs in RAS and BRAF wild-type metastatic transverse colon cancer: a clinical and molecular proof of concept study","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/esmoopen-2019-000489","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 THE AUTHORS. Published by Elsevier Limited on behalf of European Society for Medical Oncology; Originally published by BMJ.","name":"copyright","label":"Copyright"}],"article-number":"e000489"}}